Ninety One UK 13F: Cuts AstraZeneca (AZN) Stake by $200M

Ninety One UK made a major reduction in its holdings of AstraZeneca PLC (NYSE:AZN), according to a Form 13F filing submitted to the SEC on October 15, 2026. Keep in mind that 13F filings are backward-looking documents that show institutional holdings at the close of a reporting period and may not reflect current trades.

What Changed in Ninety One UK's AstraZeneca Position

The fund cut its stake in the drugmaker by 80.8%, selling 1,227,801 shares during the quarter. That move left Ninety One UK with 290,212 shares of AstraZeneca. The remaining position held a reported value of $47,343,346 at the time of the filing.

Other Institutional Activity in AstraZeneca

Other large funds made notable adjustments to their AstraZeneca shares during the same window. Investor AB kept its holding steady at 51,587,810 shares worth about $8,533,139,841. Vanguard Capital Management LLC grew its holdings by 346,803 shares, ending with 45,386,190 shares valued at roughly $7,507,329,854. Capital International Investors boosted its stake by 182,287 shares to finish with 34,576,070 shares worth about $5,719,227,865. Norges Bank expanded its position by 33,226,081 shares, reaching 33,864,172 shares worth roughly $5,601,472,814. Finally, Capital World Investors lifted its holdings by 1,811,687 shares, ending with 30,075,134 shares valued at about $4,974,728,025.

AstraZeneca PLC Stock Holds Steady

AstraZeneca shares recently traded around $166.71 as of October 16, 2026. The stock sits about 2.9% above its 50-day moving average of $162.05 and 7.9% below its 200-day moving average of $181.05. It is down 21.6% from its 52-week high of $212.71 and up 8.7% from its 52-week low of $153.41. The company has a price-to-earnings ratio of 24.72 and a forward P/E of 14.58.

Recent Earnings

AstraZeneca reported trailing-twelve-month revenue of $61.37 billion alongside earnings of $6.69 per share. The company operates with a net profit margin of 17.0% and a return on equity of 22.0%. Revenue grew 6.4% year-over-year. Investors will look toward the company's upcoming earnings release on October 30, 2026, for fresh financial details.

Dividend

AstraZeneca pays an annual dividend rate of $3.20 per share, which translates to a dividend yield of 1.92%. The payout ratio sits at 46.9% of earnings.

Analysts Set New Price Targets

On August 24, 2026, CICC initiated coverage on AstraZeneca with an outperform rating and a $198.00 price target. Across the broader Street, the stock carries a consensus buy recommendation from 12 analysts with a mean price target of $207.16.

About AstraZeneca

AstraZeneca PLC is a Cambridge, United Kingdom-based biopharmaceutical company focused on discovering, developing, and manufacturing prescription medicines across major disease areas including oncology, cardiovascular, and respiratory care. Institutional shifts in companies of this scale often draw attention from market watchers tracking large portfolio rebalancing.

Bottom Line

Ninety One UK's sharp reduction in AstraZeneca leaves it with a much smaller footprint in the healthcare giant. Market participants will watch the upcoming earnings release on October 30, 2026, to gauge business momentum, alongside subsequent institutional filings for further shifts in major holdings.